![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPRESSED PWH
|
|
|
CROI 2023 Feb 20-23
Ryan C Vargo1, Seth Robey1, Xiaowei Zang1, Lihong Du1, Bhargava Kandala1, Jessica Roberts2, Stephanie Klopfer1, Kathleen Squires1 1Merck & Co., Inc., Rahway NJ, USA; 2Simulation Plus, Cognigen Division, Buffalo, New York, USA
![0224231](../images/022523/022523-2/0224231.gif)
![0224232](../images/022523/022523-2/0224232.gif)
![0224233](../images/022523/022523-2/0224233.gif)
![0224234](../images/022523/022523-2/0224234.gif)
![0224235](../images/022523/022523-2/0224235.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|